KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Capital Expenditures (2016 - 2026)

Bio-Rad Laboratories has reported Capital Expenditures over the past 18 years, most recently at $30.0 million for Q1 2026.

  • Quarterly Capital Expenditures fell 12.79% to $30.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $153.2 million through Mar 2026, down 4.13% year-over-year, with the annual reading at $157.6 million for FY2025, 4.83% down from the prior year.
  • Capital Expenditures was $30.0 million for Q1 2026 at Bio-Rad Laboratories, down from $45.8 million in the prior quarter.
  • Over five years, Capital Expenditures peaked at $45.8 million in Q4 2025 and troughed at $17.3 million in Q2 2022.
  • The 5-year median for Capital Expenditures is $35.7 million (2023), against an average of $36.6 million.
  • Year-over-year, Capital Expenditures plummeted 38.04% in 2022 and then skyrocketed 99.83% in 2023.
  • A 5-year view of Capital Expenditures shows it stood at $34.8 million in 2022, then increased by 21.41% to $42.3 million in 2023, then grew by 1.5% to $42.9 million in 2024, then grew by 6.76% to $45.8 million in 2025, then tumbled by 34.5% to $30.0 million in 2026.
  • Per Business Quant, the three most recent readings for BIO's Capital Expenditures are $30.0 million (Q1 2026), $45.8 million (Q4 2025), and $31.7 million (Q3 2025).